11-beta-hydroxysteroid dehydrogenase · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-1411-beta-hydroxysteroid dehydrogenase shows approved-linked disease relevance led by gastroesophageal reflux disease. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P80365. Start with gastroesophageal reflux disease, then reuse UniProt P80365 as the stable protein anchor across project notes and exports.
Start with gastroesophageal reflux disease, then reuse UniProt P80365 as the stable protein anchor across project notes and exports.
11-beta-hydroxysteroid dehydrogenase shows approved-linked disease relevance led by gastroesophageal reflux disease. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with gastroesophageal reflux disease because it currently carries approved-linked support. Linked drugs include CARBENOXOLONE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxy11-beta-hydroxysteroid dehydrogenase type 2
Review this target as 11-beta-hydroxysteroid dehydrogenase, mapped to UniProt P80365. ChEMBL maps the protein component as 11-beta-hydroxysteroid dehydrogenase type 2. Sequence length is 405 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats 11-beta-hydroxysteroid dehydrogenase as ChEMBL target CHEMBL3542430, mapped to UniProt P80365. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether 11-beta-hydroxysteroid dehydrogenase is the right protein anchor across sources, using UniProt P80365 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why gastroesophageal reflux disease is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | 11-beta-hydroxysteroid dehydrogenase |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P80365 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | 11-beta-hydroxysteroid dehydrogenase type 2 |
| UniProt Accession | P80365 |
| Component Type | Protein |
| Sequence Length | 405 aa |
11-beta-hydroxysteroid dehydrogenase type 2
Review this target as 11-beta-hydroxysteroid dehydrogenase, mapped to UniProt P80365. ChEMBL maps the protein component as 11-beta-hydroxysteroid dehydrogenase type 2. Sequence length is 405 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
11-beta-hydroxysteroid dehydrogenase shows approved-linked disease relevance led by gastroesophageal reflux disease. 1 more disease program remain visible in the same review block.
Start review with gastroesophageal reflux disease because it currently carries approved-linked support. Linked drugs include CARBENOXOLONE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.